GleamWall
中文EN

XENE Xenon Pharmaceuticals Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1582313 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY-100.0%
TTM net income YoY-40.0%
TTM EPS YoY-20.6%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-50.3%
ROA-47.4%
ROIC (approx.)-48.4%
Asset turnover0.00x

Leverage & solvency

Liabilities / assets4.5%
Debt / equity0.00x
Current ratio21.19x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.83x
Accruals ratio-8.0%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue$0$0$0$0$0$0$7.50M$0
R&D expense$95.64M$99.22M$88.51M$87.70M$77.05M$74.98M$61.20M$59.47M
SG&A expense$24.42M$23.93M$23.82M$22.07M$19.28M$19.24M$19.04M$18.00M
Operating income-$120.07M-$123.16M-$112.33M-$109.77M-$96.34M-$94.23M-$72.74M-$77.48M
Pretax income-$108.59M-$111.32M-$104.87M-$104.72M-$90.22M-$85.33M-$64.62M-$69.53M
Income tax$1.84M-$585,000-$2.57M$538,000$677,000-$626,000$427,000-$3.85M
Net income-$110.44M-$110.74M-$102.30M-$105.26M-$90.90M-$84.71M-$65.05M-$65.69M
EBITDA-$119.50M-$122.60M-$111.74M-$109.16M-$95.69M-$93.60M-$72.08M-$76.84M
EPS (basic)-1.11-1.11-1.17—-1.15-1.07-0.83—
EPS (diluted)-1.11-1.11-1.17—-1.15-1.07-0.83—
Weighted avg. shares (diluted)99.77M99.61M87.35M—79.25M78.95M78.69M—
Balance sheet
Cash & equivalents$82.56M$119.53M$545.87M$199.16M$104.51M$135.38M$116.66M$142.71M
Short-term investments$868.24M$811.16M$548.88M$349.72M$357.75M$352.16M$432.97M$484.19M
Receivables———————$1.47M
Current assets$960.07M$945.87M$1.11B$560.65M$480.14M$500.25M$565.54M$635.26M
PP&E, net$7.46M$7.77M$8.29M$8.72M$8.89M$9.21M$9.70M$10.28M
Total assets$1.20B$1.30B$1.39B$633.16M$607.84M$674.28M$743.28M$798.14M
Current liabilities$45.30M$45.01M$39.81M$41.79M$38.34M$33.05M$32.03M$35.59M
Total liabilities$53.49M$53.38M$48.99M$51.40M$48.33M$40.30M$39.32M$43.24M
Shareholders' equity$1.15B$1.24B$1.34B$581.76M$559.51M$633.98M$703.96M$754.90M
Shares outstanding98.28M96.75M96.62M80.01M77.12M76.94M76.59M76.42M
Cash flow statement
Operating cash flow-$90.33M-$95.39M-$88.90M-$81.48M-$71.75M-$64.23M-$61.65M-$54.38M
Capital expenditure$284,000$275,000$133,000$318,000$281,000$157,000$43,000$783,000
Free cash flow-$90.61M-$95.67M-$89.03M-$81.80M-$72.03M-$64.39M-$61.70M-$55.17M
Investing cash flow$53.19M-$331.24M-$407.28M$62.70M$38.53M$82.26M$34.51M$98.50M
Financing cash flow$228,000$26,000$843.01M$113.54M$2.36M$65,000$1.15M$12.13M
Depreciation & amortization$562,000$558,000$587,000$611,000$641,000$632,000$659,000$633,000
Stock-based compensation$16.55M$16.73M$16.89M$14.12M$13.71M$13.71M$12.17M$13.60M

Free plan shows the latest 8 periods; Pro shows all 55 🔒

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.